Novartis SEC Filings

Novartis AG files its Form 20-F annual report describing its global pharmaceuticals business, 2025 performance context, and extensive risk profile. The company reports using IFRS in US dollars and had 1 908 151 679 ordinary shares outstanding as of year-end.

The report highlights strategic risks from global pricing and reimbursement pressure, including US measures such as the Inflation Reduction Act and “maximum fair price” agreements, and notes the loss of US exclusivity for Entresto in July 2025. It stresses dependence on successful R&D, protection of intellectual property, and competitive product launches.

Novartis discusses recent acquisitions (including Anthos Therapeutics, Regulus Therapeutics and Tourmaline Bio) and integration risks, as well as challenges in implementing AI, major IT programs, and managing cybersecurity, data privacy and complex supply chains. The company discloses USD 27.9 billion of non-current financial debt and USD 5.6 billion of current financial debt, and outlines exposure to geopolitical, macroeconomic, climate, tax and regulatory changes.

Novartis AG has filed proxy-related materials describing its proposed acquisition of Avidity Biosciences, Inc. through a merger in which Novartis would indirectly acquire all outstanding Avidity shares. The transaction is linked to a planned spin-off or sale of Atrium Therapeutics, Inc. (“SpinCo”) from Avidity.

Avidity will prepare and deliver a definitive proxy statement and proxy card to its stockholders in advance of a special meeting to vote on the transactions. The materials emphasize that stockholders should read the definitive proxy statement and related SEC filings because they will contain important information about the deals and the parties involved.

The communication explains that Novartis, Avidity, SpinCo and certain of their directors, officers and employees may be considered participants in the proxy solicitation, and refers investors to existing SEC filings for details on their interests. It also includes extensive forward-looking statements language, noting that completion of the transactions is subject to customary closing conditions, including regulatory approvals and approval by Avidity stockholders, and highlighting risks such as potential delays, higher-than-expected costs, competing offers, business disruption and possible stockholder litigation.

Novartis AG has filed proxy materials related to its proposed acquisition of Avidity Biosciences, Inc., which will be paired with a spin-off or sale of Atrium Therapeutics, Inc. (SpinCo). An internal message to Avidity employees explains that, following closing of the transaction, Stephen Moran, currently a Novartis executive, is expected to become Managing Director of Avidity Biosciences and will work with Avidity’s leadership to preserve its culture, AOC platform and pipeline.

The communication emphasizes that until closing, Novartis and Avidity remain separate companies, with no changes to existing structures or reporting lines. It also notes that Avidity will send a definitive proxy statement and proxy card to its stockholders ahead of a special meeting to vote on the transactions, and urges investors to read that document when available. Extensive forward-looking statement language highlights that completion of the deal, the SpinCo separation and expected benefits are subject to risks, including regulatory and stockholder approvals and potential business disruptions.

Novartis AG announced that the US FDA has approved Itvisma (onasemnogene abeparvovec-brve), the first and only gene replacement therapy for children two years and older, teens, and adults with spinal muscular atrophy (SMA) who have a confirmed SMN1 gene mutation. Itvisma delivers a one-time, fixed intrathecal dose that does not need to be adjusted for age or body weight and is designed to replace the missing or defective SMN1 gene.

The approval is supported by Phase III STEER and Phase IIIb STRENGTH studies, where Itvisma showed statistically significant improvement and stabilization in motor function over 52 weeks with a safety profile consistent across both trials. The therapy is intended to reduce reliance on chronic SMA treatments and will be available in the US in December, with Novartis offering patient support services to assist with access and insurance navigation.

Novartis AG updated its medium-term outlook, projecting a 5-6% constant-currency sales CAGR for 2025-2030, supported by strong existing products and a broad pipeline. Peak sales guidance was raised for key cancer drugs, with Kisqali lifted from USD 8 billion+ to USD 10 billion+ and Scemblix from USD 3 billion+ to USD 4 billion+.

The company now counts eight de‑risked, in‑market assets each targeting USD 3-10 billion in peak sales and expects 15+ potentially submission‑enabling clinical readouts over the next two years. Novartis reported a core operating income margin of 41.2% for the first nine months of 2025 and aims to sustain 40%+ margins by 2029 while absorbing dilution from its planned acquisition of Avidity Biosciences, which is expected to close in the first half of 2026, subject to conditions.

Novartis AG filed a Form 6-K reporting the issuance by Novartis Capital Corporation of multiple U.S. dollar notes, with related documents incorporated into an existing Form F-3. The tranches include: $800,000,000 Floating Rate Notes due 2028, $700,000,000 3.900% Notes due 2028, $1,750,000,000 4.100% Notes due 2030, $925,000,000 4.300% Notes due 2032, $925,000,000 4.600% Notes due 2035, $350,000,000 5.200% Notes due 2045, and $550,000,000 5.300% Notes due 2055.

The filing lists the terms agreement, forms of guaranteed debt securities, an officer’s certificate, and legal opinions to support the issuance and their inclusion in the shelf registration.

Novartis Capital Corporation, fully guaranteed by Novartis AG, launched a multi‑tranche U.S. dollar notes offering. The deal includes $800,000,000 floating‑rate notes due November 5, 2028, plus fixed‑rate tranches of $700,000,000 at 3.900% due 2028, $1,750,000,000 at 4.100% due 2030, $925,000,000 at 4.300% due 2032, $925,000,000 at 4.600% due 2035, $350,000,000 at 5.200% due 2045, and $550,000,000 at 5.300% due 2055.

The floating‑rate notes pay Compounded SOFR plus 0.52% with quarterly payments starting February 5, 2026; fixed‑rate tranches pay semiannually each May 5 and November 5, commencing May 5, 2026. The notes are senior unsecured, pari passu with the issuer’s other senior debt, and the guarantees rank equally with Novartis AG’s other senior unsecured obligations.

Estimated net proceeds are about $5,959.3 million, intended for general corporate purposes outside Switzerland, including refinancing of existing long‑ and short‑term debt. Fixed‑rate notes may be redeemed at the issuer’s option as described, and all series include tax‑related redemption provisions. The notes will not be listed, and settlement via DTC, Clearstream, and Euroclear is expected on or about November 5, 2025.

Novartis Capital Corporation launched a preliminary prospectus supplement under its shelf registration to offer senior unsecured notes across multiple tranches, including a floating‑rate series using Compounded SOFR and fixed‑rate series maturing from 2028 to 2055. The notes will be fully and unconditionally guaranteed by Novartis AG and issued in book‑entry form through DTC, with access via Clearstream and Euroclear. There is no sinking fund.

Novartis may redeem the fixed‑rate notes at its option as described, and both the fixed and floating tranches may be redeemed for certain tax reasons. The notes will not be listed, and an active trading market may not develop. Key risks noted include potential price volatility with interest rates and credit ratings, structural subordination to subsidiary liabilities, effective subordination to any future secured debt, and SOFR‑related benchmark risks for the floating‑rate tranche. Net proceeds will be used for general corporate purposes outside Switzerland, including refinancing existing indebtedness.

Novartis filed definitive additional proxy materials regarding its proposed acquisition of Avidity Biosciences (RNA), outlining strategic rationale and next steps. CEO Vasant Narasimhan highlighted Avidity’s antibody-oligonucleotide conjugate platform, which pairs monoclonal antibodies with siRNA or antisense oligonucleotides to target tissues beyond the liver, with a focus on muscle for neuromuscular diseases.

The materials describe plans tied to Avidity’s programs in myotonic dystrophy (DM1), facioscapulohumeral muscular dystrophy (FSHD) and Duchenne muscular dystrophy (DMD). Novartis stated it raised guidance to 6% sales growth over the next five years and expects a core margin of 40%+ in 2029, and noted more investment given the potential acquisition. Avidity will file a preliminary and definitive proxy for a special meeting related to the Transactions, which also contemplate a spin-off or sale of SpinCo and a merger. The filing includes customary cautionary and solicitation disclosures.

Novartis filed definitive additional proxy materials regarding its proposed acquisition of Avidity Biosciences (RNA), outlining strategic rationale and next steps. CEO Vasant Narasimhan highlighted Avidity’s antibody-oligonucleotide conjugate platform, which pairs monoclonal antibodies with siRNA or antisense oligonucleotides to target tissues beyond the liver, with a focus on muscle for neuromuscular diseases.

The materials describe plans tied to Avidity’s programs in myotonic dystrophy (DM1), facioscapulohumeral muscular dystrophy (FSHD) and Duchenne muscular dystrophy (DMD). Novartis stated it raised guidance to 6% sales growth over the next five years and expects a core margin of 40%+ in 2029, and noted more investment given the potential acquisition. Avidity will file a preliminary and definitive proxy for a special meeting related to the Transactions, which also contemplate a spin-off or sale of SpinCo and a merger. The filing includes customary cautionary and solicitation disclosures.